Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

Abstract Background Upadacitinib, a Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in patients with ankylosing spondylitis (AS) in the phase III SELECT-AXIS programs. We report the 1-year efficacy and safety in patients with AS and an inadequate response to biolog...

Full description

Bibliographic Details
Main Authors: Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert D. Inman, Hideto Kameda, Yihan Li, Xianwei Bu, Anna Shmagel, Peter Wung, In-Ho Song, Atul Deodhar
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Arthritis Research & Therapy
Subjects:
Ankylosing spondylitis
Janus kinase inhibitor
Open-label extension
Upadacitinib
Biologic
Tumor necrosis factor
Online Access:https://doi.org/10.1186/s13075-023-03128-1

Internet

https://doi.org/10.1186/s13075-023-03128-1

Similar Items